Two phenotypes have been proposed: insomnia with objective near-normal sleep duration, related to increased psychological symptoms, and insomnia with objective short sleep duration, associated with cardiometabolic morbidity. Reduced heart rate variability has also been implicated in the pathophysiology of cardiometabolic disease; however, there are little data on whether cardiovascular function differs between patients with objective short sleep duration and near-normal sleep duration. Participants (M age = 49.9 AE 11.3 years; 62.8% female) were 180 adults with chronic insomnia (M duration = 15.7 AE 13.6). Objective sleep duration was based on total sleep time averaged across two consecutive nights of polysomnography and subjective sleep duration was based on 2-week sleep diaries. The sample was divided into two groups, with sleep duration shorter (polysomnography-total sleep time: n = 46; sleep diary: n = 95) or equal/longer (polysomnography-total sleep time: n = 134; sleep diary: n = 85) than 6 hr. Electrocardiogram data derived from polysomnography were used to obtain heart rate and heart rate variability during stage 2 (N2) and rapid eye movement sleep. Heart rate variability measures included absolute and normalized highfrequency component, an index of parasympathetic activation, and the ratio of lowto high-frequency (LF/HF ratio), an index of sympathovagal balance. After controlling for covariates (e.g., co-morbidity), patients with objective short sleep duration had reduced high-frequency (p < .05) and elevated low-frequency/high-frequency ratio (p = .036) and heart rate (p = .051) compared with patients with near-normal sleep duration. No differences were observed between phenotypes when subjective sleep duration was used. Insomnia patients with objective short sleep duration showed significantly dampened parasympathetic activation and increased sympathovagal imbalance relative to their counterparts with near-normal sleep duration. These findings highlight the importance of treating insomnia, as treatment may reduce the risk of cardiovascular disease.
short sleep duration (OSSD; PSG-defined TST <6 hr). These authors have reported that objective sleep duration provides information on the natural course of insomnia, biological severity, as well as health and treatment outcomes (Vgontzas et al., 2013) . Insomnia with NNSD is related with an anxious-ruminative profile (Vgontzas et al., 2013) , whereas insomnia with OSSD is linked with physiological hyperarousal (Vgontzas et al., 2001) , increased risk of type 2 diabetes, hypertension, as well as concurrent and future cerebrovascular and cardiovascular events (Fernandez-Mendoza et al., 2012; Vgontzas et al., 2009) . Despite data on the link between insomnia and OSSD with cardiometabolic disease (Fernandez-Mendoza et al., 2012; Kalmbach, Pillai, Arnedt, & Drake, 2016; Vgontzas et al., 2009 ), information on potential underlying pathophysiological mechanisms, such as systematic inflammation (Fernandez-Mendoza et al., 2017) , hormonal and metabolic dysregulation (D'Aurea et al., 2015; Fernandez-Mendoza et al., 2014) , or alterations in the autonomic nervous system (Miller et al., 2016; Spiegelhalder et al., 2011) have been scant.
Non-invasive indicators of the autonomic nervous system include heart rate (HR), controlled by both the sympathetic and parasympathetic nervous systems, as well as heart rate variability (HRV), which is largely influenced by the parasympathetic nervous system (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996) .
HRV is a quantitative marker reflecting the variations between continuous heartbeats, and is considered a quantifiable measure of cardiovascular autonomic function (Task Force of the European
Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996) . While elevated HRV is representative of a healthy cardiovascular autonomic function, dampened HRV (i.e., parasympathetic withdrawal) is significantly associated with a 32%-45% increased risk of cardiovascular morbidity (Hillebrand et al., 2013) . More specifically, nocturnal HRV is independently associated with increased risk of the initiation, progression (e.g., subclinical inflammation, glucose concentration, plasma fibrinogen) and development of cardiovascular disease in otherwise healthy populations (Jarczok, Li, Mauss, Fischer, & Thayer, 2013) . While evidence suggests low HRV is associated with more severe sleep disturbances (Von K€ anel, Thayer, & Fischer, 2009) , within the context of insomnia, findings vary across studies (Dodds, Miller, Kyle, Marshall, & Gordon, 2017) . To the best of our knowledge, only two studies have investigated differences in HRV and HR between insomnia phenotypes (Miller et al., 2016; Spiegelhalder et al., 2011) .
In a recent investigation, cluster analyses were conducted on several objective PSG variables and, while it was not the focus of the study, two insomnia clusters were identified. Unlike previous studies that used cut-off scores, these phenotypes were based on average PSG-TST of 4.82 and 6.5 hr (Miller et al., 2016) . Authors documented significantly reduced HRV during sleep onset among insomnia volunteers with OSSD relative to those with NNSD; however, no differences were found for HR. In another study (Spiegelhalder et al., 2011) , instead of PSG-TST, PSG-derived sleep efficiency (SE) was used to classify insomnia phenotypes. Nevertheless, significantly reduced HRV was observed in patients with PSG-SE <85% relative to patients with PSG-SE ≥85%; no differences in HR were found. Interestingly, these authors also assessed selfreported sleep duration; however, rather than compare HRV and HR between patients with subjective short and near-normal sleep duration, patients with subjective short sleep duration were only compared with healthy controls.
Given that objective (and not subjective) sleep duration is posited to be the most biologically severe phenotype of insomnia on future health morbidity and mortality (Vgontzas et al., 2013) , and because there are limited data in the field thus far, the primary objective of the present study was to explore whether HRV and HR differ between clinical insomnia patients with OSSD (<6 hr) and NNSD (≥6 hr). To provide further evidence, a secondary objective of the present study was to examine whether HRV and HR differ between insomnia phenotypes with short or NNSD based on TST derived from sleep diaries.
| MATERIALS AND METHODS
The present study is based on secondary analyses of data extracted from two clinical trials. The first trial was conducted in Universit e Laval (Qu ebec) and examined the impact of different treatment sequences using cognitive behavioural therapy for insomnia (CBT-I) with and without zolpidem. The second trial was conducted in two sites: Universit e Laval (Qu ebec) and University of California, Berkeley (Berkeley). This clinical trial examined the unique impact of behaviour therapy and cognitive therapy compared with complete CBT-I. The detailed descriptions of study protocols, participants, and results pertaining to the primary research questions of these studies have been reported by Morin et al. (2009) and Harvey and colleagues (B elanger et al., 2016; Harvey et al., 2014) , respectively.
| Study context and participants
Recruitment strategies and inclusion criteria were similar in both parent studies. In general, participants were recruited through advertisements and referrals from health care practitioners. Exclusion criteria included: (1) sleep-altering medication (e.g., steroids)-patients using prescribed or over-the-counter sleep medications no more than twice weekly were enrolled after they withdrew from the medications; (2) evidence of sleep apnea (apneahypopnea index >15), restless legs syndrome, or periodic limb movements during sleep (movement index with arousal >15 hr); (3) night-shift work or irregular bed/wake time; (4) diagnosis of psychotic, bipolar disorder or substance abuse-patients using alcohol as a sleep aid were also required to reduce or discontinue this practice for the study; (5) presence of unstable/progressive medical condition(s) or neurological degenerative disease-patients with stable medical (e.g., hypertension) or psychiatric disorders (e.g., anxiety)
were included in the study provided that these conditions were not the primary cause of insomnia.
Additional exclusion criteria for the first trial (Morin et al., 2009) included history of suicide attempt. Additional exclusion criteria for the second clinical trial (B elanger et al., 2016; Harvey et al., 2014) had poor ECG data. In total, 180 participants were included in the present study.
| Measures
The present article focused exclusively on participant's baseline measures prior to receiving treatment.
| Sleep diary
Participants completed daily sleep diaries for two weeks during the baseline period. The sleep diary is a standard assessment instrument in insomnia research, which allows for prospectively monitoring sleep patterns in the patient's home. The variables derived from sleep diaries included: sleep-onset latency (SOL), wake time after sleep onset (WASO), total sleep time (TST), time spent in bed, SE, and self-rated sleep quality. TST from the daily sleep diaries were averaged over two weeks, and used to create two groups with short sleep duration (<6 hr: n = 95) or with NNSD (≥6 hr: n = 85).
| Insomnia Severity Index
The ISI (Morin et al., 2011 ) is a 7-item, patient-reported outcome questionnaire used to assess the perceived severity of night-time and daytime symptoms of insomnia over the past month. Specifically, items addressed sleep problems, sleep (dis)satisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems, and distress/worry caused by sleep difficulties. Each item was rated on a five-point Likert scale, with higher scores representative of severe insomnia. The ISI is a reliable and valid instrument to detect cases of insomnia in the population, and is positively correlated with subjective sleep estimates (Morin et al., 2011) .
| Beck Depression Index
The Beck Depression Index (BDI) (Beck, Steer, & Carbin, 1988 ) is a 21-item self-reported questionnaire that assesses the presence and the intensity of depressive symptoms experienced during the past 2 weeks. Each item was rated on a four-point Likert scale, with higher scores indicative of greater depressive symptomatology. OSSD was defined as PSG-TST shorter than 6 hr, and NNSD was defined as PSG-TST equal to or more than 6 hr.
| Polysomnography
2.2.5 | Heart rate variability and heart rate During PSG, continuous raw ECG data were acquired using the Stellate Harmonie 5.2 at a sampling rate of 1 kHz. ECG data were derived from a modified Lead-II configuration. Research demonstrates that using one night of ECG data from PSG is sufficient to obtain reliable (i.e., high short-term stability) HRV estimates in insomnia patients (Isreal et al., 2012) and, thus, ECG data of the last night of each evaluation were analyzed and the beat-by-beat RR intervals edited by visual inspection (Kubios â HRV 2.2).
As recommended by the Task Force of the European Society of
Cardiology and the North American Society of Pacing and
Electrophysiology (1996), 2-min HRV epochs were analyzed to obtain low-frequency (LF)-HRV (0.04-0.15 Hz). Based on stringent criteria (Trinder et al., 2001) , epochs for N2 and REM sleep stages were identified over the sleep period (wake periods were excluded) and all possible epochs were selected; a majority of the participants did not have sufficient N3 data and, thus, only data for N2 and REM sleep were analyzed in the present study. Identified 2-min artifact HRV epochs were then analyzed across the sleep period and averaged across sleep stages.
Power spectral estimates included LF-HRV and high-frequency power band (HF; 0.15-0.40 Hz). HF was used as an index of parasympathetic activation, and the ratio of low-to high-frequency (LF/HF ratio) was used as an index of sympathovagal balance (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996) . While the physiological component for HF is well established, the LF/HF ratio is posited to represent important functional significance and adverse health consequences 
| RESULTS
Overall, patients were predominantly white (89.6%), female (62.8%), married (65.0%), middle-aged (M age = 49.9 years, SD = 11.3), completed an average of 15.5 years of education (SD = 3.5) and had normal BMI (M = 24.9 kg/m 2 , SD = 3.6 kg/m 2 ). Of the total sample, 40.0% had reported using hypnotic medication for sleep in the last month prior to the study. In terms of co-morbidity, 42 (23.3%)
patients presented a co-morbid psychiatric disorder (most commonly anxiety), and 110 patients (61.1%) presented at least one co-morbid medical disorder (most commonly musculoskeletal disorders and hypertension). Within the subsample of patients with hypertension (n = 14), 13 reported taking medication including beta-blockers (n = 2), angiotension II receptor blockers (n = 4), calcium channel blockers (n = 2), diuretics (n = 2), and angiotension converting enzyme inhibitors (n = 3). Descriptive data of sample characteristics are summarized in 
| Sleep duration based on sleep diaries
When TST was based on sleep diaries, no significant differences between patients with short sleep duration and NNSD were docu- Similar to the present study, past research found evidence of parasympathetic withdrawal among short sleepers with insomnia.
More specifically, reduced frequency-and time-domain HRV (i.e., rMSSD, pNN50) were significantly reduced among insomnia patients with OSSD during sleep initiation (Spiegelhalder et al., 2011) or with low PSG-SE over the course of sleep (Miller et al., 2016) relative to counterparts. However, unlike the present study, previous findings only found non-significant trends for LF/HF ratio and HR between insomnia phenotypes (Miller et al., 2016; Spiegelhalder et al., 2011) , which could be explained by differences in methodology and/or measurement across studies (e.g., 2-min versus The present non-significant findings when subjective TST was used are consistent with the notion that insomnia with OSSD is the most biologically severe phenotype (Vgontzas et al., 2013) . To the best of our knowledge, this is the first study to examine modifications in the autonomic nervous system in insomnia patients with subjectively-derived sleep duration. The non-significant findings may be explained by the incongruity of comparing subjectively-and objectively-measured variables. Indeed, similar non-significant results have been documented when sleep duration was based on selfreports and outcomes were based on objective indices (Shivashankar et al., 2017) . Conversely, when sleep duration and health outcomes were both subjective, significant associations were observed (Kalmbach et al., 2016) .
Given that the consequences associated with this phenotype (insomnia with OSSD) are related with hyperarousal and increased risk of medical morbidity/mortality (Vgontzas et al., 2013 One strength of the present study was the relatively large sample comprised of patients suffering from insomnia on average for 15 years, which provided an opportunity to examine HRV and HR within a clinical sample. Second, this is (to the best of our knowledge) the first study to investigate autonomic cardiovascular function in insomnia patients with short and NNSD derived from sleep diaries (over 14 days) and two consecutive nights of PSG. Third, ECG data were not influenced by wake periods across the night, as stringent criteria were used to identify stable sleep stages with artifact-free epochs (i.e., no intrusion from wake/artifact into clean epochs). Finally, the present findings were robust, even when controlling for relevant covariates, including socio-demographics, anthropometrics, medical and psychological co-morbidity, and insomnia severity.
Given that insomnia, OSSD, and autonomic cardiovascular function are involved in a complex regulatory system, it is important to consider the other factors that may contribute to these associations as casual variables, mediators, and/or moderators (e.g., health status, menopause, medication use). Thus, it is suggested that prospective study designs with both clinical and population-based samples should be conducted to obtain more precise identification of such variables. Future longitudinal research with ecological validity (e.g., ambulatory PSG) can be used to better elucidate and test the temporal nature of this relation. Future research should also examine these associations with other objective sleep parameters in conjunction with subjective ratings, as it would be beneficial to examine agreement across sleep variables between groups. Notably, while statistically significant differences were observed in HRV between phenotypes, to the best of our knowledge, there are yet no clinically defined nocturnal HRV values that identify those at risk (similar to systolic and diastolic blood pressure values that identify hypertension). As such, studies assessing the clinical applicability of nocturnal HRV and HR in risk stratification of insomnia patients at high risk of morbidity/mortality are needed. Indeed, few studies have examined the impact of cognitive behavioural therapy on insomnia patients with OSSD and NNSD (Bathgate, Edinger, & Krystal, 2017; Lovato, Lack, & Kennaway, 2016; Rochefort, Jarrin, Ivers, & Morin, 2016) .
Thus, it is worthwhile to consider interventions that directly influence and promote autonomic functioning in insomnia patients with OSSD. For example, acupuncture, which has direct effects on the autonomic nervous system, has been associated with changes in blood pressure, pupil size, skin conductance, microneurography recorded muscle sympathetic nerve activity, HR, and HRV (Huang, Kutner, & Bliwise, 2011) .
In sum, the present findings provide new evidence on the potential role parasympathetic withdrawal and/or sympathovagal imbalance may play in the increased risk of insomnia with OSSD. 
CONFLI CT OF INTERESTS

